Zenicor (ZENI) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached 7,085 KSEK, a 5% increase year-over-year, marking the highest quarterly revenue to date.

• Operating income turned positive at 158 KSEK, compared to -1,084 KSEK in Q1 2024, the third consecutive profitable quarter.

• Key contract signed with two university hospitals in the UK for Zenicor Solution, valued at approximately 800,000 SEK.

• SAFER study in the UK completed its screening phase, with over 23,000 screened using Zenicor One and more than 800 atrial fibrillation cases detected.

Financial highlights

• Revenue: 7,085 KSEK in Q1 2025, up from 6,726 KSEK in Q1 2024.

• Operating income: 158 KSEK, up from -1,084 KSEK year-over-year.

• Earnings per share: 0.02 SEK, compared to -0.12 SEK in Q1 2024.

• Cash flow from operations was negative, with period-end cash at 343 KSEK, down from 912 KSEK at the start of the quarter.

• Total assets at quarter-end: 62.5 MSEK; equity: 28.0 MSEK.

Outlook and guidance

• Several procurement processes ongoing in Sweden and Finland, with decisions expected during the year.

• Continued focus on sales growth and delivery to customers to support stable cash flow and long-term profitability.

• SAFER study results expected to influence future atrial fibrillation screening and stroke prevention internationally.